[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=8b3bbcf240edfa15a9e533954eaa3ed225a6beff1aa1e3acab5e59c645b165fc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756399560,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 136623487,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=8b3bbcf240edfa15a9e533954eaa3ed225a6beff1aa1e3acab5e59c645b165fc"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma",
    "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Regeneron Pharmaceuticals, Inc. is placed second among the best cancer stocks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company recognized for advancing cancer treatment through innovative immunotherapies and biologics. Its flagship PD-1 inhibitor, Libtayo, is the standard of care for advanced cutaneous squamous cell […]",
    "url": "https://finnhub.io/api/news?id=aa0183f070be3cfd756a4d0029024c29cbbbc68d1ba7956df2330b9e1997abc4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756371657,
      "headline": "FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)’s Linvoseltamab for Multiple Myeloma",
      "id": 136558123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Regeneron Pharmaceuticals, Inc. is placed second among the best cancer stocks. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is a biopharmaceutical company recognized for advancing cancer treatment through innovative immunotherapies and biologics. Its flagship PD-1 inhibitor, Libtayo, is the standard of care for advanced cutaneous squamous cell […]",
      "url": "https://finnhub.io/api/news?id=aa0183f070be3cfd756a4d0029024c29cbbbc68d1ba7956df2330b9e1997abc4"
    }
  }
]